VIIBRYD Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Viibryd, and when can generic versions of Viibryd launch?

Viibryd is a drug marketed by Abbvie and is included in one NDA.

The generic ingredient in VIIBRYD is vilazodone hydrochloride. There are fourteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the vilazodone hydrochloride profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Viibryd

A generic version of VIIBRYD was approved as vilazodone hydrochloride by TEVA PHARMS USA on September 30^th, 2019.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for VIIBRYD?
What are the global sales for VIIBRYD?
What is Average Wholesale Price for VIIBRYD?

Summary for VIIBRYD

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	85
Clinical Trials:	16
Patent Applications:	500
Drug Prices:	Drug price information for VIIBRYD
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for VIIBRYD
What excipients (inactive ingredients) are in VIIBRYD?	VIIBRYD excipients list
DailyMed Link:	VIIBRYD at DailyMed

Drug patent expirations by year for VIIBRYD

Recent Clinical Trials for VIIBRYD

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Forest Laboratories	Phase 1
New York State Psychiatric Institute	Phase 4
Forest Laboratories	Phase 3

See all VIIBRYD clinical trials

Paragraph IV (Patent) Challenges for VIIBRYD

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VIIBRYD	Tablets	vilazodone hydrochloride	10 mg, 20 mg, and 40 mg	022567	5	2015-01-21

US Patents and Regulatory Information for VIIBRYD

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011	AB	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011	AB	RX	Yes	No	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for VIIBRYD

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-001	Jan 21, 2011	⤷ Sign Up	⤷ Sign Up
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-003	Jan 21, 2011	⤷ Sign Up	⤷ Sign Up
Abbvie	VIIBRYD	vilazodone hydrochloride	TABLET;ORAL	022567-002	Jan 21, 2011	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

International Patents for VIIBRYD

See the table below for patents covering VIIBRYD around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
European Patent Office	0648767	Dérivés de piperidine et piperazine qui puissent agir sur le "CNS" (Piperdine and piperazine derivatives which affect the C.N.S.)	⤷ Sign Up
Canada	2782521		⤷ Sign Up
China	100384841		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

AI Research Assistant

Questions you can ask:

Summary for VIIBRYD

Recent Clinical Trials for VIIBRYD

Paragraph IV (Patent) Challenges for VIIBRYD

Make Better Decisions: Try a trial or see plans & pricing